Pharma-Bio Serv US, Inc.

1250 Germantown Pike
Suite 301
Plymouth Meeting
Pennsylvania
19462
United States

Tel: 215-997-3310

Email: info@pharmabioserv.com

Show jobs for this employer

About Pharma-Bio Serv US, Inc.

Pharma-Bio Serv is a global regulatory compliance service leader in the life science industry. We provide a broad range of cGMP compliance consulting services, project management, validation, technology transfer, laboratory and technical training services to Pharma, Biotech and medical device manufacturers worldwide. Our differentiator is the quality of our staff and the creativity and leadership of our management. With 18 years of regulated industry support experience, what guarantees that our customer relationships keep developing and growing, is our commitment and performance track record in meeting or better exceeding our clients’ expectations and compliance needs.
Throughout the different project lifecycles, we offer solutions to get the work done on time, under control, at competitive costs, while we add value by combining a talented professional workforce with our years of experience for a complete holistic solution. Proven record delivering quality, consistency, cost effective award-winning results to our customers globally… because our common goal is to be In Compliance!
For more information on our locations and services visit our website: www.pharmabioserv.com

2 articles about Pharma-Bio Serv US, Inc.

  • Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV) today announced that revenues for the quarter ended January 31, 2024 were approximately $2.4 million, a decrease of approximately $1.9 million when compared to the same period last year.

  • Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced it has filed its Quarterly Report on Form 10-Q for the quarter ended July 31, 2020.